WASHINGTON Pharmaceutical agencies Genentech and OSI
pharmaceuticals LLC will pay $sixty seven million to remedy allegations they
made deceptive statements approximately the effectiveness of lung cancer drug
Tarceva, the U.S. Justice department said on Monday.
The claims alleged that between 2006 and 2011, the agencies
misrepresented the effectiveness of Tarceva to physicians and different
healthcare companies to deal with sure sufferers with non-small mobile lung
cancer, the branch said in a statement.
As a part of the settlement, the federal authorities gets
$sixty two.6 million and state Medicaid packages will get $four.four million.
Medicaid is the joint U.S.
federal-nation healthcare program for the poor.
"We trust our Tarceva promotional communications and
practices have been and are entirely right and in compliance with the
regulation," said Holli Kolkey, a spokeswoman for Genentech, a unit of
Swiss drugmaker Roche conserving AG (ROG.S).
Kolkey added that the agreement allows the company to avoid
civil litigation.
Astellas Pharma Inc (4503.T), which sold U.S.
biotech OSI pharmaceuticals for $four billion in coins in 2010, said that it
had determined to remedy the matter expeditiously, and mentioned that the
alleged behavior preceded the deal.
No comments:
Post a Comment